Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Capital Expenditures (2021 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Capital Expenditures for 3 consecutive years, with -$36.0 as the latest value for Q4 2023.

  • Quarterly Capital Expenditures fell 100.04% to -$36.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $34301.0 through Dec 2023, down 67.97% year-over-year, with the annual reading at $34301.0 for FY2023, 67.97% down from the prior year.
  • Capital Expenditures hit -$36.0 in Q4 2023 for Pasithea Therapeutics, up from -$22659.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $92725.0 in Q4 2022 to a low of -$22659.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $17148.3 across 3 years, with a median of $5486.0 in 2022.
  • Biggest YoY gain for Capital Expenditures was 2662.07% in 2023; the steepest drop was 513.03% in 2023.
  • Year by year, Capital Expenditures stood at $12933.0 in 2021, then skyrocketed by 616.96% to $92725.0 in 2022, then crashed by 100.04% to -$36.0 in 2023.
  • Business Quant data shows Capital Expenditures for KTTA at -$36.0 in Q4 2023, -$22659.0 in Q3 2023, and $3108.0 in Q2 2023.